• Get ready to energize your life?

    Top Offers Only Today

    Support your health and step-up your mental focus

  • Get ready to energize your life?

    Top Offers Only Today

    Support your health and step-up your mental focus

  • Get ready to energize your life?

    Top Offers Only Today

    Support your health and step-up your mental focus

>

Gina guidelines bronchial asthma 2010 ppt

post in: Health Date:08 Oct 2017, 10:46 views:869

Gina guidelines bronchial asthma 2010 ppt

1Allergological and Pneumological Service, Department of associates Pediatric, University. D'Annunzio, 66100 Chieti, atlanta Italy 2Department of Pediatric, University.

D'Annunzio, 66100 Chieti, Italy. Copyright 2010 Marcello Verini. This is an open access article distributed under the.

Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The aim of this study was to verify FeNO usefulness, as a marker of bronchial inflammation, in the assessment of therapeutic management of childhood asthma.

guidelines

We performed a prospective 1-year randomized clinical trial evaluating two groups of 32 children with allergic asthma: gina group, in which therapy was assessed only by gina guidelines and FeNO group, who followed a therapeutic program assessed also on FeNO measurements. Asthma Severity score (ASs Asthma Exacerbation Frequency (AEf and Asthma Therapy score (ATs) were evaluated at the start of the study (T1 6 months (T2 and 1 year after (T3).

ASs and, aEf significantly decreased only in the FeNO group at times T2 and T3 ( pT1-T2.0001, and pT1-T3.01; pT1-T2.0001; and pT1-T3.0001, resp.). After six months of follow-up, we found a significant increase of patients under inhaled corticosteroid and/or antileukotrienes in the gina group compared to the FeNO group ( ).

Our data show that FeNO measurements, might be a very useful additional parameter for management of asthma, which is able to avoid unnecessary inhaled corticosteroid and antileukotrienes therapies, however, mantaining a treatment sufficient to obtain a meaningful improvement of asthma. Introduction, asthma is characterized by variable degrees of airway obstruction, hyperresponsiveness, and chronic inflammation. Current guidelines emphasize that inhaled corticosteroids (ICSs) represent the main treatment for asthma because they target the underlying airways inflammation.

Actually decisions to start ICSs and/or long-acting 2-adrenergic agonist (laba) and/or antileukotrienes (a-LT or change the dose are mainly based on symptoms reported by the child or parents.

 

TOP FREE OFFERS TODAY TEST WEBSITE